Open AccessChemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer
Author(s) -
B.R. Mancini,
Stacey Stein,
Shane Lloyd,
Charles E. Rutter,
Edward Samuel James,
Bryan Chang,
Jill Lacy,
Kimberly L. Johung
Publication year - 2018
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo.2018.04.03
Subject(s) - medicine , folfirinox , pancreatic cancer , general surgery , oncology , cancer , oxaliplatin , colorectal cancer
The safety and efficacy of FOLFIRINOX (FX) followed by consolidative chemoradiation (CRT) in borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) has not been extensively studied. We sought to evaluate outcomes and toxicities of this regimen.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom